Page 31 - 2020-2021-Heroes-Program-Bklt-v1_fa_Neat

ACS honors Pfizer for LORBRENA, a third-generation ALK inhibitor specifically
designed by Pfizer scientists to inhibit the most common tumor mutations that drive

resistance to current medications and to address metastases in the brain. It was first
approved in 2018 for people with previously treated ALK-positive NSCLC, and in 2021
received an expanded approval for those newly diagnosed with the disease.

Simon Bailey
Simon Bailey is Executive Vice President Drug Discovery, Plexium Inc. Prior to joining Plexium,
he led medicinal chemistry departments at Pfizer and initiated the project that led to Lorbrena.
Throughout his career, he has had an interest in applying the benefits of molecular complexity,
such as macrocycles, to drug design.

Benjamin Burke
Ben is an Associate Research Fellow in Oncology Medicinal Chemistry at Pfizer. He worked on
antiviral and oncology projects, leading to drug approvals. He received his Ph.D. in Medicinal
Chemistry from the University of Illinois in Chicago. His computational chemistry career started
at Agouron Pharmaceuticals focusing on structure-based drug design.

Michael Collins
Michael Collins is a Senior Principal Scientist at Pfizer and has a B.S. in Chemistry from
Duquesne University and M.S. in Chemistry from the University of Pittsburgh.

Jingrong Jean Cui
Jingrong Jean Cui received her Ph.D. from The Ohio State University, and her M.S. and B.S. from the
University of Science and Technology of China. Jean was the lead inventor of Crizotinib and
Lorlatinib when she worked at Pfizer. She is now the founder and CEO of BlossomHill Therapeutics.

#HeroesofChemistry 31